NCT04703764View on ClinicalTrials.gov

A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

January 20, 2022

Study Completion Date

February 3, 2022

Conditions
Obesity
Interventions
DRUG

HSG4112

Once-daily, 14-day multiple oral administration

DRUG

Placebo

Once-daily, 14-day multiple oral administration

Trial Locations (2)

41944

Kyungpook National University Hospital, Daegu

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Glaceum
All Listed Sponsors
collaborator

Kyungpook National University Hospital

OTHER

collaborator

Seoul National University Hospital

OTHER

lead

Glaceum

INDUSTRY

NCT04703764 - A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112 | Biotech Hunter | Biotech Hunter